Eric Sciorilli News Today

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx....

FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary...

25.10.2023 - FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members ...

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the e...

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration and continue to support the requested product shelf lifeSubmission of...

Prior Approval Supplement for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription Drug User Fee Act goal date of October 30, 2023 by the U.S. Food and Drug Administration ... -Today at 08:02 am- MarketScreener

Prescription Drug User Fee Act goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12,... | June 12, 2023

FLORHAM PARK, N.J., June 01, 2023 -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced... | June 1, 2023

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and...

Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid... | May 23, 2023